Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
Not applicable · Testing Etrasimod administration · 1 site · Showa Inan General Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing Etrasimod administration (a drug) as a possible treatment. Condition(s) listed: Ulcerative Colitis (Disorder).
It is open-label: participants know what they are receiving.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Age range not stated in the record
- Any sex
Some of the main requirements, copied from the record:
- Patients with active ulcerative colitis
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 30 participants are expected to take part.
- Start date: 2025-10-01.
- Main results expected around 2027-09-30 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Japan.
Main thing being measured
- Primary endpoint: Clinical remission rate at 4 weeks (Clinical activity Index score <4) (max.29, min. 0) (4 weeks)
In the researchers’ words
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Ulcerative Colitis (Disorder) |
| Lead sponsor | Showa Inan General Hospital |
| Enrollment | 30 (estimated) |
| Start date | 2025-10-01 |
| Primary completion (est.) | 2027-09-30 |
| First posted | 2025-11-24 |
| Last updated | 2026-07-21 |
| Official title | A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis |
| ClinicalTrials.gov ID | NCT07243639 |
Interventions
- Etrasimod administration (Drug)
2 mg of Etrasimod is orally administered everyday.
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients with active ulcerative colitis Exclusion Criteria: * the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Showa Inan General Hospital | Komagane, Nagano | Japan | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.